DE69721749D1 - Eprosartandihydrat und ein verfahren zu seiner herstellung und formulierung - Google Patents

Eprosartandihydrat und ein verfahren zu seiner herstellung und formulierung

Info

Publication number
DE69721749D1
DE69721749D1 DE69721749T DE69721749T DE69721749D1 DE 69721749 D1 DE69721749 D1 DE 69721749D1 DE 69721749 T DE69721749 T DE 69721749T DE 69721749 T DE69721749 T DE 69721749T DE 69721749 D1 DE69721749 D1 DE 69721749D1
Authority
DE
Germany
Prior art keywords
eprosartand
dihydrate
formulation
production
eprosartand dihydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69721749T
Other languages
English (en)
Other versions
DE69721749T2 (de
Inventor
R Palepu
M Venkatesh
Sarma Duddu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69721749(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE69721749D1 publication Critical patent/DE69721749D1/de
Publication of DE69721749T2 publication Critical patent/DE69721749T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE69721749T 1996-03-29 1997-03-26 Eprosartandihydrat und ein verfahren zu seiner herstellung und formulierung Expired - Lifetime DE69721749T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1441496P 1996-03-29 1996-03-29
US14414P 1996-03-29
PCT/US1997/004877 WO1997036874A1 (en) 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation

Publications (2)

Publication Number Publication Date
DE69721749D1 true DE69721749D1 (de) 2003-06-12
DE69721749T2 DE69721749T2 (de) 2004-03-25

Family

ID=21765344

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69721749T Expired - Lifetime DE69721749T2 (de) 1996-03-29 1997-03-26 Eprosartandihydrat und ein verfahren zu seiner herstellung und formulierung

Country Status (36)

Country Link
EP (1) EP0889880B1 (de)
JP (1) JP4316013B2 (de)
CN (2) CN1214682A (de)
AP (1) AP901A (de)
AR (1) AR006439A1 (de)
AT (1) ATE239723T1 (de)
AU (1) AU726694B2 (de)
BG (1) BG64095B1 (de)
BR (1) BR9708336A (de)
CA (1) CA2250395C (de)
CZ (1) CZ293345B6 (de)
DE (1) DE69721749T2 (de)
DK (1) DK0889880T3 (de)
DZ (1) DZ2199A1 (de)
EA (1) EA001958B1 (de)
EG (1) EG23889A (de)
ES (1) ES2198564T3 (de)
HK (1) HK1016594A1 (de)
HU (1) HU228263B1 (de)
ID (1) ID16507A (de)
IL (1) IL126319A0 (de)
MA (1) MA24437A1 (de)
MY (1) MY117682A (de)
NO (2) NO311760B1 (de)
NZ (1) NZ332008A (de)
OA (1) OA11176A (de)
PL (1) PL188816B1 (de)
PT (1) PT889880E (de)
RO (1) RO118870B1 (de)
SK (1) SK282346B6 (de)
TR (1) TR199801954T2 (de)
TW (1) TW434239B (de)
UA (1) UA49880C2 (de)
UY (1) UY24504A1 (de)
WO (1) WO1997036874A1 (de)
ZA (1) ZA972686B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262102B1 (en) * 1997-06-27 2001-07-17 Smithkline Beecham Corporation Eprosartan monohydrate
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
AU750611B2 (en) * 1997-11-17 2002-07-25 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
ID25640A (id) 1998-03-04 2000-10-19 Takeda Chemical Industries Ltd Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
WO2000004862A2 (en) * 1998-07-20 2000-02-03 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
GB9820405D0 (en) 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
AU1157500A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
DK1197223T3 (da) * 1999-04-28 2005-05-30 Takeda Pharmaceutical Farmaceutisk præparat til forebyggelse, behandling eller udviklingsinhibition af simpel retinopati eller præproliferativ retinopati
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
CZ20023381A3 (cs) * 2000-04-12 2003-02-12 Novartis Ag Kombinované farmaceutické prostředky obsahující antagonistu AT1-receptoru nebo/a inhibitor HMG-CoA reduktázy nebo/a ACE inhibitor
AU2002364381A1 (en) * 2001-11-23 2003-06-10 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
RU2004137109A (ru) * 2002-05-17 2005-10-10 Новартис АГ (CH) Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP3045174A1 (de) 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medikament zur vorbeugung und behandlung von arteriosklerose und bluthochdruck
WO2009013760A2 (en) 2007-07-25 2009-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101333216A (zh) 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids

Also Published As

Publication number Publication date
ZA972686B (en) 1997-09-29
HUP9902769A3 (en) 2000-04-28
EP0889880A4 (de) 1999-06-23
AU2547097A (en) 1997-10-22
EP0889880A1 (de) 1999-01-13
EG23889A (en) 2007-12-12
TR199801954T2 (xx) 1998-12-21
DE69721749T2 (de) 2004-03-25
PT889880E (pt) 2003-09-30
HU228263B1 (en) 2013-02-28
NZ332008A (en) 1999-05-28
IL126319A0 (en) 1999-05-09
HK1016594A1 (en) 1999-11-05
HUP9902769A2 (hu) 2000-03-28
EA001958B1 (ru) 2001-10-22
MY117682A (en) 2004-07-31
UA49880C2 (uk) 2002-10-15
CA2250395C (en) 2005-09-06
CZ293345B6 (cs) 2004-04-14
SK282346B6 (sk) 2002-01-07
WO1997036874A1 (en) 1997-10-09
ES2198564T3 (es) 2004-02-01
AR006439A1 (es) 1999-08-25
AU726694B2 (en) 2000-11-16
BR9708336A (pt) 1999-08-03
OA11176A (en) 2003-05-13
JP2000508632A (ja) 2000-07-11
ID16507A (id) 1997-10-02
MA24437A1 (fr) 1998-10-01
EA199800873A1 (ru) 1999-02-25
BG102822A (en) 1999-11-30
PL329046A1 (en) 1999-03-01
PL188816B1 (pl) 2005-04-29
RO118870B1 (ro) 2003-12-30
CN1332167A (zh) 2002-01-23
TW434239B (en) 2001-05-16
NO984503D0 (no) 1998-09-28
CZ310198A3 (cs) 1999-03-17
BG64095B1 (bg) 2003-12-31
DZ2199A1 (fr) 2002-12-03
NO311760B1 (no) 2002-01-21
EP0889880B1 (de) 2003-05-07
DK0889880T3 (da) 2003-09-01
NO984503L (no) 1998-09-28
AP9700956A0 (en) 1997-04-30
NO2002005I1 (no) 2002-09-02
SK132298A3 (en) 1999-03-12
CN1214682A (zh) 1999-04-21
ATE239723T1 (de) 2003-05-15
UY24504A1 (es) 1997-09-19
CA2250395A1 (en) 1997-10-09
JP4316013B2 (ja) 2009-08-19
AP901A (en) 2000-11-23

Similar Documents

Publication Publication Date Title
DE69721749D1 (de) Eprosartandihydrat und ein verfahren zu seiner herstellung und formulierung
DE69532895D1 (de) Biomaterial und verfahren zu dessen herstellung
DE69716129D1 (de) Seitlich ausdehnbarer tampon und verfahren zu seiner herstellung
DE69929311D1 (de) Oximanderivate und verfahren zu ihrer herstellung
DE69710484D1 (de) Übergezogene süsswaren und verfahren zu deren herstellung
ATE216704T1 (de) Propiophenonderivate und verfahren zu ihrer herstellung
DE69504892D1 (de) Mischelement und Verfahren zu dessen Herstellung
DE69922815D1 (de) Gipsplatte und verfahren zu ihrer herstellung
DE69930254D1 (de) Mikroströmungstechnischer gebenstand und verfahren zu seiner herstellung
ATE379971T1 (de) Disinfektionsmittel und verfahren zu dessen herstellung
DE69529065D1 (de) Härtbare zusammensetzung und verfahren zu ihrer herstellung
DE69731059D1 (de) Gebäudeeinheit, modulare gebäudekunstruktion und verfahren zu seiner herstellung
DE69729941D1 (de) Beschleunigungsmesselement sowie verfahren zu seiner herstellung
DE69611599D1 (de) Halbaromatische polyamidzusamensetzung und verfahren zu ihrer herstellung
DE69942382D1 (de) Sensor und verfahren zu dessen herstellung
DE59800305D1 (de) Formteil und verfahren zu seiner herstellung
DE69524599D1 (de) Antiblockmittel und verfahren zu seiner herstellung
DE69628237D1 (de) Polyestergegenstand und verfahren zu seiner herstellung
DE69603829D1 (de) Schalwandler und verfahren zu dessen herstellung
DE69524684D1 (de) Photosensor und Verfahren zu dessen Herstellung
DE59803104D1 (de) Messwertaufnehmer und ein verfahren zu dessen herstellung
DE69941258D1 (de) Polyisocyanat und verfahren zu seiner herstellung
DE69625176D1 (de) Camptothecin-derivate und verfahren zu ihrer herstellung
DE69905326D1 (de) Sollerschlitz und Verfahren zu dessen Herstellung
DE69801795D1 (de) Indolyl-pyrrolylidenmethylpyrrol-derivate und verfahren zu ihrer herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition